# RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.

> **NCT02746744** · PHASE3 · COMPLETED · sponsor: **Anders Svenningsson** · enrollment: 200 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Dimethyl fumarate
- **DRUG:** Sodium Chloride solution

## Key facts

- **NCT ID:** NCT02746744
- **Lead sponsor:** Anders Svenningsson
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2021-07
- **Final completion:** 2021-08
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02746744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02746744, "RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02746744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*